Psychopharmacology for Children and Adolescents

Massachusetts General Hospital Handbook of General Hospital Psychiatry

Volumn , Issue , 2004, Pages 411-445

  Prince, Jefferson B ^a,b,c   Wilens, Timothy E ^a,b   Biederman, Joseph ^a,b   Spenser, Thomas J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NORTH SHORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745215903     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-02767-0.50029-2     Document Type: Chapter

References (231)

1. Hoagwood K, Rupp A Mental health service needs, use, and costs for children and adolescents with mental disorders and their families: preliminary evidence. Mental Health, United States, 1994 1994, 52-64. U.S. Department of Health and Human Services, Washington, DC. C.C.F.M.H. Services (Ed.).
2. Jensen PS, Bhatara VS, Vitiello B, et al. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999, 38:557-565.
3. Popper C Psychiatric pharmacosciences of children and adolescents 1987, American Psychiatric Press, Washington, DC.
4. Gutgesell H, Atkins D, Barst R, et al. AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999, 38:979-982.
5. Physicians desk reference 1995, Medical Economics Data Production Company, Montvale, NJ.
6. Hemmer SA, Pasternak JF, Zecker SG, et al. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001, 24:99-102.
7. Steiner H, Saxena K, Chang K Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr 2003, 8:298-308.
8. Wilens T, Biederman J, Spencer T Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997, 36:45-48.
9. Bernstein G, Shaw K AACAP official action-practice parameters for the assessment and treatment of anxiety disorders. Am J Psychiatry 1993, 32:1089-1098.
10. Bernstein G, Borchardt C, Perwein A Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996, 35:1110-1119.
11. Winston FK, Kassam-Adams N, Garcia-Espana F, et al. Screening for risk of persistent posttraumatic stress in injured children and their parents (comment). JAMA 2003, 290:643-649.
12. Saxe G, Stoddard F, Courtney D, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry 2001, 40:915-921.
13. Kessler R, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995, 52:1048-1060.
14. Famularo R Psychiatric comorbidity in childhood posttraumatic stress disorder. Child Abuse Negl 1996, 20:953-961.
15. Donnelly CL Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child Adolesc Psychiatr Clin North Am 2003, 12:251-269.
16. Donnelly CL, Amaya-Jackson L, March JS Psychopharmacology of pediatric posttraumatic stress disorder. J Child Adolesc Psychopharmacol 1999, 9:203-220.
17. Pfefferbaum JD Posttraumatic stress disorder in children: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997, 36:1503-1511.
18. Klein R, Koplewicz H, Kanner A Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992, 31:21-28.
19. Sachdev P Akathisia and restless legs 1995, Cambridge University Press, New York.
20. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. ed 4.
21. Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002, 41:1431-1438.
22. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial(comment). J Am Acad Child Adolesc Psychiatry 2001, 40:773-779.
23. March J, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive compulsive disorder: a multicenter double-blind placebo controlled study. JAMA 1998, 280:1752-1756.
24. Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:1175-1181.
25. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001, 40:222-229.
26. Garvey MA, Perlmutter SJ, Allen AJ, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999, 45:1564-1571.
27. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases (comment) [erratum appears in Am J Psychiatry 1998 Apr;155(4):578]. Am J Psychiatry 1998, 155:264-271.
28. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292-299.
29. Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330-336.
30. Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of Tourette's syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31-39.
31. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette's syndrome. Neurology 2003, 60:1130-1135.
32. Margolese HC, Annable L, Dion Y Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychopharmacol 2002, 63:1040-1044.
33. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50-56.
34. Tourette's Syndrome Study G Treatment of ADHD in children with tics: a randomized controlled trial (comment). Neurology 2002, 58:527-536.
35. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649-656.
36. Gilbert DL, Sethuraman G, Sine L, et al. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000, 54:1310-1315.
37. Lipinski JF, Sallee FR, Jackson C, et al. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997, 12:402-407.
38. Silver AA, Shytle RD, Sheehan KH, et al. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:1103-1110.
39. Silver AA, Shytle RD, Sanberg PR Mecamylamine in Tourette's syndrome: a two-year retrospective case study. J Child Adolesc Psychopharmacol 2000, 10:59-68.
40. Sanberg PR, Silver AA, Shytle RD, et al. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 1997, 74:21-25.
41. Hoopes SP Donepezil for Tourette's disorder and ADHD. J Clin Psychopharmacol 1999, 19:381-382.
42. Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydro-cannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002, 35:57-61.
43. Pediatrics AAo, Committee on Quality Improvement SoA-DHD Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000, 105:1158-1170.
44. Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998, 279:1100-1107.
45. Wilens T, Biederman J, Spencer T: Attention deficit hyperactivity disorder. In Caskey CT, editor: Annual Review of Medicine, vol 53, 2002, pp 113-131.
46. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002, 41:26S-49S.
47. Barkley R Attention-deficit/hyperactivity disorder: a handbook for diagnosis and treatment 1998, Guilford Press, New York. ed 2.
48. Barkley RA International consensus statement on ADHD. J Am Acad Child Adolesc Psychiatry 2002, 41:1389.
49. American Academy of Pediatrics, Committee on Quality Improvement SoA-DHD Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:1033-1044.
50. Dulcan M Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997, 36:85S-121S.
51. Wilens T, Spencer T Pharmacology of amphetamines. Handbook of substance abuse: neurobehavioral pharmacology 1998, 501-513. Plenum Press, New York. R. Tarter, R. Ammerman, P. Ott (Eds.).
52. Wilens T, Spencer T The stimulants revisited. Child and adolescent psychiatric clinics of north America 2000, vol 9:573-603. VVB Saunders, Philadelphia. C. Stubbe (Ed.).
53. Wolraich M, Greenhill LL, Concerta Study Group Randomized controlled trial of OROS Methylphenidate qd in children with attention deficit/hyperactivity disorder. Pediatrics 2001, 108:883-892.
54. Greenhill L: Efficacy and safety of OROS methylphenidate in adolescents with ADHD, American Academy of Child and Adolescent Psychiatry, San Francisco, 2002, Poster Presentation 4.
55. Greenhill LL, Findling RL, Swanson JM A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyper-activity disorder. Pediatrics 2002, 109:E39.
56. Arnold LE Methylphenidate vs. amphetamine: comparative review. J Atten Disord 2000, 3:200-211.
57. Pliszka SR, Browne RG, Olvera RL, et al. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000, 39:619-626.
58. Biederman J, Newcorn J, Sprich S Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991, 148:564-577.
59. Wilens T, Faraone S, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
60. Spencer T, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?. J Am Acad Child Adolesc Psychiatry 1996, 35:1460-1469.
61. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159:1896-1901.
62. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:E83.
63. Ring BJ, Gillespie JS, Eckstein JA, et al. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002, 30:319-323.
64. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001, 11:251-265.
65. Ascher JA, Cole JO, Colin J, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995, 56:395-401.
66. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion SR in adolescents with combined attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001, 40:307-314.
67. Wilens T, Biederman J, Baldessarini R, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996, 35:1491-1501.
68. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. efficacy. J Am Acad Child Adolesc Psychiatry 1989, 28:777-784.
69. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991, 30:104-108.
70. Biederman J, Thisted RA, Greenhill L, et al. Estimation of the association between desipramine and the risk for sudden death in 5- to 14- year old children. J Clin Psychiatry 1995, 56:87-93.
71. Daly J, Wilens T The use of tricyclic antidepressants in children and adolescents. Pedi Clin North Am 1998, 45:1123-1135.
72. Hunt R, Capper L, O'Connell P Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1990, 1:87-102.
73. Hunt RD, Inderaa RB, Cohen DJ The therapeutic effect of clonidine and attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 1986, 22:229-236.
74. Connor DF, Fletcher KE, Swanson JM A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999, 38:1551-1559.
75. Connor DF, Barkley RA, Davis HT A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000, 39:15-25.
76. Schvehla TJ, Mandoki MW, Sumner GS Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit. South Med J 1994, 87:692-695.
77. Singer HV, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo controlled study with clonidine and desipramine. Pediatrics 1995, 95:74-81.
78. Steingard R, Biederman J, Spencer T, et al. Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993, 32:350-353.
79. Wilens TE, Biederman J, Spencer T Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994, 33:424-426.
80. Prince J, Wilens T, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996, 35:599-605.
81. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992, 53:77-82.
82. Roden DM, Nadeau JHJ, Primm RK Electrophysiologic and hemodynamic effects of chronic oral therapy with the alpha 2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther 1988, 43:648-654.
83. Buccafusco JJ Neuropharmacology and behavioral actions of clonidine: interactions with central neurotransmitters. Int Rev Neurobiol 1992, 33:55-107.
84. Wilens T Straight talk about psychiatric medications for kids, 1999 2002, Guilford Press, New York.
85. Nami R, Bianchini C, Fiorella G, et al. Comparison of effects of guanfacine and clonidine on blood pressure, heart rate, urinary catecholamines, and cyclic nucleotides during and after administration to patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1983, 5:546-551.
86. Leckman JF, Ort S, Caruso KA, et al. Rebound phenomena in Tourette's syndrome after abrupt withdrawal of clonidine: behavioral, cardiovascular, and neurochemical effects. Arch Gen Psychiatry 1986, 43:1168-1176.
87. Jaffe R, Livshits T, Bursztyn M Adverse interaction between clonidine and verapamil. Ann Pharmacother 1994, 28:881-883.
88. Swanson J, Flockhart D, Udrea D, et al. Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharmacol 1995, 5:301-304.
89. Popper CW Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 1995, 5:157-166.
90. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999, 38:614-619. discussion 619-622,.
91. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995, 34:1140-1146.
92. Horrigan JP, Barnhill LJ Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995, 5:215-223.
93. Scahill L Controlled clinical trial of guanfacine in ADHD youth with tic disorders 2000, NCDEU, Boca Raton.
94. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067-1074.
95. Horrigan JP, Barnhill LJ Guanfacine and secondary mania in children. J Affect Disord 1999, 54:309-314.
96. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. ed 4.
97. Rushton JL, Clark SJ, Freed GL Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics 2000, 105:E82.
98. Rushton JL, Clark SJ, Freed GL Primary care role in the management of childhood depression: a comparison of pediatricians and family physicians (comment). Pediatrics 2000, 105:957-962.
99. Fleming JE, Offord DR Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 1990, 29:571-580.
100. Kashani JH, Beck NC, Hoeper EW, et al. Psychiatric disorders in a community sample of adolescents. Am J Psychiatry 1987, 144:584-589.
101. Kashani J, Schmid LS Epidemiology and etiology of depressive disorders. Clinical guide to depression in children and adolescents 1992, 43-64. American Psychiatric Press, Washington, DC. M. Shafii, S. Shafii (Eds.).
102. Lewinsohn P, Hops H, Roberts R, et al. Adolescent psychopathology: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993, 102:133-144.
103. Rushton J, Forcier M, Schectman R Epidemiology of depressive symptoms in the national longitudinal study of adolescent health. J Am Acad Child Adolesc Psychiatry 2002, 41:199-205.
104. Department of Health and Human Services Mental health: a report of the surgeon general, Rockville 1999, U.S. Public Health Service, MD.
105. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry 1996, 35:1427-1439.
106. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years: II. J Am Acad Child Adolesc Psychiatry 1996, 35:1575-1583.
107. Birmaher B, Brent DA, Benson RS Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. (comment). J Am Acad Child Adolesc Psychiatry 1998, 37:1234-1238.
108. Lewinsohn P, Clarke G, Seely J, et al. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994, 33:809-818.
109. Wade T, Cairney J, Pevalin D Emergence of gender differences in depression during adolescence: national panel results from three countries. J Am Acad Child Adolesc Psychiatry 2002, 41:190-198.
110. Kovacs M Gender and the course of major depressive disorder through adolescence in clinically referred youngsters. J Am Acad Child Adolesc Psychiatry 2001, 40:1079-1085.
111. Biederman J, Faraone S, Mick E, et al. Psychiatric comorbidity among referred juveniles with major depression: Fact or artifact?. J Am Acad Child Adolesc Psychiatry 1995, 34:579-590.
112. Kovacs M, Feinberg TL, Crouse-Novak MA, et al. Depressive disorders in childhood: a longitudinal prospective study of characteristics and recovery. Arch Gen Psychiatry 1984, 41:229-237.
113. Biederman J, Spencer T Depressive disorders in childhood and adolescence: a clinical perspective. J Child Adolesc Psychopharmacol 1999, 9:233-237.
114. Luby JL, Heffelfinger AK, Mrakotsky C, et al. The clinical picture of depression in preschool children. J Am Acad Child Adolesc Psychiatry 2003, 42:340-348.
115. Kovacs M Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996, 35:705-715.
116. Kovacs M, Feinberg TL, Crouse-Novak M, et al. Depressive disorders in childhood: a longitudinal study of the risk for a subsequent major depression. Arch Gen Psychiatry 1984, 41:643-649.
117. Emslie G, Rush A, Weinberg W, et al. Recurrence of major depressive disorder in hospitalized children and adolescents. J Am Acad Child Adolesc Psychiatry 1997, 36:785-792.
118. Wickramaratne PJ, Greenwald S, Weissman MM Psychiatric disorders in the relatives of probands with prepubertal-onset or adolescent-onset major depression. J Am Acad Child Adolesc Psychiatry 2000, 39:1396-1405.
119. Wickramaratne PJ, Weissman MM Onset of psychopathology in offspring by developmental phase and parental depression. J Am Acad Child Adolesc Psychiatry 1998, 37:933-942.
120. Geller B, Zimerman B, Williams M, et al. Adult psychosocial outcome of prepubertal major depressive disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:673-677.
121. Geller B, Fox L, Clark K Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994, 33:461-468.
122. Strober M, Carlson G Predictors of bipolar illness in adolescents with major depression: a follow-up investigation. J Adolesc Psychiatry 1982, 10:299-319.
123. Bowden CL, Rhodes LJ Mania in children and adolescents: recognition and treatment. Psychiatric Ann 1996, 26:S430-S434.
124. Gould MS, Greenberg T, Veiling DM, et al. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2003, 42:386-405.
125. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. J Am Acad Child Adolesc Psychiatry 2001, 40:24S-51S.
126. Kovacs M, Akiskal HS, Gatsonis C, et al. Childhood-onset dysthymic disorder: clinical features and prospective naturalistic outcome. Arch Gen Psychiatry 1994, 51:365-374.
127. Zito JM, Safer DJ Services and prevention: pharmacoepidemiology of antidepressant use. Biol Psychiatry 2001, 49:1121-1127.
128. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000, 283:1025-1030.
129. Zito JM, Safer DJ, dosReis S, et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002, 109:721-727.
130. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective (comment). Arch Pediatr Adolesc Med 2003, 157:17-25.
131. Walkup J Increasing use of psychotropic medications in children and adolescents: what does it mean?. J Child Adolesc Psychopharmacol 2003, 13:1-3.
132. Geller B, Reising D, Leonard HL, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999, 38:513-516.
133. Ryan ND Medication treatment for depression in children and adolescents. CNS Spectr 2003, 8:283-287.
134. Bostic J, Wilens T, Spencer T, et al. Pharmacologic treatment of juvenile depression. Child Adolesc Psychiatr Clin North Am 1999, 6:175-191.
135. Anonymous Prozac for pediatric use. FDA Consumer 2003, 37:3.
136. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997, 54:1031-1037.
137. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002, 41:1205-1215.
138. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003, 290:1033-1041.
139. Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 1999, 38:566-572.
140. Wagner KD, Robb AS, Findling R, et al: Citalopram treatment of pediatric depression: results of a placebo-controlled trial, American College of Neuropsy-chopharmacology. Waikoloa, Hawaii, 2001.
141. Cheer SM, Figgitt DP Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents [erratum appears in Paediatr Drugs 3(11):801, 2001]. Paediatric Drugs 2001, 3:763-781.
142. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001, 40:762-772.
143. Teicher MH, Glod C, Cole JO Emergence of intense suicidal preoccupation during fluoxetine treatment (comment). Am J Psychiatry 1990, 147:207-210.
144. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003, 160:790-792.
145. Mandoki MW, Tapia MR, Tapia MA, et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997, 33:149-154.
146. Findling RL, Preskorn SH, Marcus RN, et al. Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 2000, 39:1008-1016.
147. Wilens T, Spencer T, Biederman J, et al. Case study: nefazodone for juvenile mood disorders. J Am Acad Child Adolesc Psychiatry 1997, 36:481-485.
148. Emslie G A double-blind placebo controlled study of nefazodone in depressed children and adolescents 2002, New Drug Clinical Evaluation Unit, Boca Raton, Fla.
149. Cozza KL, Armstrong SC, Oesterheld JR Concise guide to drug interaction principles for medical practice 2003, American Psychiatric Press, Washington, DC.
150. Wilens TE, Cohen L, Biederman J, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002, 22:568-575.
151. Axelson DA, Perel JM, Birmaher B, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002, 41:1037-1044.
152. Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999, 38:952-959.
153. Reis M, Olsson G, Carlsson B, et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002, 22:406-413.
154. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Psychopharmacol 2001, 41:770-778.
155. Aranda-Michel J, Koehler A, Bejarano PA, et al. Nefazodone-induced liver failure: report of three cases. Ann Intern Med 1999, 130:285-288.
156. Goodman E, Capitman J Depressive symptoms and cigarette smoking among teens. Pediatrics 2000, 106:748-755.
157. Masand PS, Gupta S Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002, 14:175-182.
158. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002, 156:696-701.
159. Wilens TE, Biederman J, March JS, et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999, 38:573-577.
160. Walkup J, Labellarte M Complications of SSRI treatment. J Child Adolesc Psychopharmacol 2001, 11:1-4.
161. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (comment). Biol Psychiatry 1998, 44:77-87.
162. Zajecka J, Tracy KA, Mitchell S Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997, 58:291-297.
163. Sher L Prevention of the serotonin reuptake inhibitor discontinuation syndrome. Med Hypotheses 2002, 59:92-94.
164. Ali S, Milev R Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature. Can J Psychiatry 2003, 48:258-264.
165. Geller B, Luby J Child and adolescent bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997, 36:1168-1176.
166. Biederman J Developmental subtypes of juvenile bipolar disorder. Harv Rev Psychiatry 1995, 3:227-230.
167. McClellan J, Werry J, Ayres W, et al: Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder.
168. Biederman J, Birmaher B, Carlson GA, et al. National Institute of Mental Health Research Roundtable on Prepubertal Bipolar Disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:871-878.
169. Wozniak J, Biederman J, Kiely K, et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry 1995, 34:867-876.
170. Biederman J Resolved: mania is mistaken for ADHD in prepubertal children. J Am Acad Child Adolesc Psychiatry 1998, 37:1091-1096. discussion 1096-1099,.
171. Spencer TJ, Biederman J, Wozniak J, et al. Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behavior disorders. Biol Psychiatry 2001, 49:1062-1070.
172. Geller B, Sun K, Zimennan H, et al. Complex and rapid-cycling in bipolar children and adolescents: a preliminary study. J Affect Disord 1995, 34:259-268.
173. Geller B, Zimerman B, Williams M, et al. Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000, 10:157-164.
174. Biederman J, Mick E, Faraone SV Pediatric mania: a developmental subtype of bipolar disorder? (comment). Biol Psychiatry 2000, 48:458-466.
175. Strober M, Schmidt-Lackner S, Freeman R, et al. Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up. J Am Acad Child Adolesc Psychiatry 1995, 34:724-731.
176. Strober M, Morrell W, Lampert C, et al. Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. Am J Psychiatry 1990, 147:457-461.
177. Schurhoff F, Bellivier F, Jouvent R, et al. Early and late onset bipolar disorders: two different forms of manic-depressive illness?. J Affect Disord 2000, 58:215-221.
178. Biederman J, Mick E, Bostic J, et al. The naturalistic course of pharmacologic treatment of children with manic like symptoms: a systematic chart review. J Clin Psychiatry 1998, 59:628-637.
179. Biederman J, Mick E, Spencer TJ, et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000, 10:185-192.
180. Weller EB, Weller RA, Fristad MA Lithium dosage guide for prepubertal children: a preliminary report. J Am Acad Child Adolesc Psychiatry 1986, 25:92-95.
181. Geller B, Cooper T, Sun K, et al. Double-blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry' 1998, 37:171-178.
182. Alessi N, Naylor MW, Ghaziuddin M, et al. Update on lithium carbonate therapy in children and adolescents. J Am Acad Child Adolesc Psychiatry 1994, 33:291-304.
183. Woolston J Case study: carbamazepine treatment of juvenile-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999, 38:335-338.
184. Wozniak J, Biederman J, Richards JA Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. J Clin Psychiatry 2001, 62:10-15.
185. Pleak RR, Birmaher B, Gavrilescu A, et al. Mania and neuropsychiatric excitation following carbamazepine. J Am Acad Child Adolesc Psychiatry 1988, 27:500-503.
186. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000, 39:713-720.
187. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2002, 41:1224-1230.
188. Stahl S What makes an antipsychotic atypical?. J Clin Psychiatry 1998, 59:402-404.
189. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo- controlled study: The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000, 57:841-849.
190. Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001, 11:239-250.
191. Lindenmayer JP, Nathan AM, Smith RC Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001, 62:30-38.
192. Jin H, Meyer JM, Jeste DV Phenomenology of and risk factors for new-onset diabetes mellitus an diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002, 14:59-64.
193. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000, 20:220-225.
194. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999, 38:960-965.
195. Green WH Child & adolescent clinical psychopharmacology 2001, 2001. Lippincott Williams & Wilkins, Philadelphia.
196. Delbello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002, 41:1216-1223.
197. Wang PW, Ketter TA Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull 2002, 36:44-66.
198. Mandoki M Lamontrigine/valproate in treatment resistant bipolar disorder in children and adolescents. Biol Psychiatry 1997, 41:93S-94S.
199. Roy Chengappa KN, Levine J, Rathore D, et al. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001, 16:186-190.
200. Tanguay PE Pervasive developmental disorders: a 10-year review. J Am Acad Child Adolesc Psychiatry 2000, 39:1079-1095.
201. State M, King B, Dykens E Mental retardation: a review of the past 10 years: II. J Am Acad Child Adolesc Psychiatry 1997, 36:1664-1671.
202. King BH, State MW, Shah B, et al. Mental retardation: a review of the past 10 years: I. J Am Acad Child Adolesc Psychiatry 1997, 36:1656-1663.
203. Volkrnar FR, Klin A, Schultz RT, et al. Asperger's disorder. Am J Psychiatry 2000, 157:262-267.
204. Pearson DA, Santos CW, Roaehe JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2003, 42:209-216.
205. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with sub-average intelligence. Am J Psychiatry 2002, 159:1337-1346.
206. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems (comment). N Engl J Med 2002, 347:314-321.
207. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001, 40:887-894.
208. McDougle GJ, Kem DL, Posey DJ Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002, 41:921-927.
209. Ratey JJ, Mikkelsen E, Sorgi P, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol 1987, 7:35-41.
210. Ratey JJ, Bemporad J, Sorgi P, et al. Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 1987, 17:439-446.
211. Ratey JJ, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989, 50:382-384.
212. Niederhofer H, Staffen W, Mair A Lofexidine in hyperactive and impulsive children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2002, 41:1396-1397.
213. Jaselskis CA, Cook EH, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992, 12:322-327.
214. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992, 53:77-82.
215. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 2001, 4:119-125.
216. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder (comment). Arch Gen Psychiatry 1996, 53:1001-1008.
217. Horvath K Secretin treatment for autism (comment). New Engl J Med 2000, 342:1216. discussion 1218,.
218. Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Assoc Acad Minority Physicians 1998, 9:9-15.
219. Unis AS, Munson JA, Rogers SJ, et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism (comment). J Am Acad Child Adolesc Psychiatry 2002, 41:1315-1321.
220. Sandler AD, Sutton KA, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder (comment). New Engl J Med 1999, 341:1801-1806.
221. Sponheim E, Oftedal G, Helverschou SB Multiple doses of secretin in the treatment of autism: a controlled study. Acta Paediatr 2002, 91:540-545.
222. McClellan J, Werry J Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1994, 33:616-635.
223. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997, 36:694-700.
224. Martin A, L'Ecuyer S Triglyceride, cholesterol and weight changes among risperidone-treated youths: a retrospective study. Eur Child Adolesc Psychiatry 2002, 11:129-133.
225. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000, 10:259-268.
226. Bryden KE, Carrey NJ, Kutcher SP Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 2001, 11:113-130.
227. Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003, 42:170-175.
228. Sholevar EH, Baron DA, Hardie TL Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000, 10:69-78.
229. Remschmidt H, Schulz E, Martin M An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994, 4:31-41.
230. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine trial. Arch Gen Psychiatry 1996, 53(12):1090-1097.
231. Gammon GD, Brown TE Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993, 3:1-10.